NasdaqGM:IOVABiotechs
A Look At Iovance Biotherapeutics (IOVA) Valuation After Strong Amtagvi Data And Growing Pipeline Momentum
Amtagvi data and pipeline momentum reshape the story for Iovance Biotherapeutics (IOVA)
The latest move in Iovance Biotherapeutics (IOVA) has been driven by real world data for its Amtagvi cell therapy that outperformed pivotal trial results, together with growing attention on upcoming NSCLC data and wider pipeline progress.
See our latest analysis for Iovance Biotherapeutics.
At a share price of $3.47, Iovance has seen a 4.52% 1 day share price return and 37.70% year to date share price...